Skip to main content
Erschienen in: American Journal of Clinical Dermatology 6/2001

01.12.2001 | Current Opinion

Do Women Have More Adverse Drug Reactions?

verfasst von: Dr Marius Rademaker

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2001

Einloggen, um Zugang zu erhalten

Abstract

Up to 5% of all hospital admissions are the result of adverse drug reactions (ADRs). Identifying those factors which may predispose to ADRs is essential for risk management. Amongst the known risk factors for adverse reactions are increasing age, polypharmacy, liver and renal disease as well as being female. Female patients have a 1.5- to 1.7-fold greater risk of developing an ADR, including adverse skin reactions, compared with male patients. The reasons for this increased risk are not entirely clear but include gender-related differences in pharmacokinetic, immunological and hormonal factors as well as differences in the use of medications by women compared with men.
Women generally have a lower lean body mass, a reduced hepatic clearance, have differences in activity of cytochrome P450 (CYP) enzymes (40% increase in CYP3A4, varied decrease in CYP2D6, CYP2C19 and CYP1A2), and metabolize drugs at different rates compared with men. Other important factors include conjugation, absorption, protein binding and renal elimination, which may all have some gender-based differences. However, how these differences result in an increased risk of ADRs is not clear.
There are pharmacodynamic differences between men and women, seen particularly with cardiac and psychotropic medications. There is no doubt that chlorpromazine, fluspirilene and various antipsychotics appear more effective in women than men for the same dosage and plasma concentration. Similarly, women are at increased risk of QT prolongation with certain anti-arrhythmic drugs compared with men even at equivalent serum concentrations. The mechanisms are unknown.
Increasingly the evidence is that idiosyncratic drug reactions, particularly cutaneous reactions, appear to have an immunological etiology. It is possible that gender difference in T cell activation and proliferation account for this as well as the increased prevalence of skin diseases such as systemic lupus erythematosus and photosensitivity. Whatever the mechanism(s), it is important to be aware that gender is a significant factor in ADRs.
Literatur
1.
Zurück zum Zitat Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999; 83: 665-700 Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999; 83: 665-700
2.
Zurück zum Zitat Leape L.L., Brennan T.A., Laird N., et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–384PubMedCrossRef Leape L.L., Brennan T.A., Laird N., et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–384PubMedCrossRef
3.
Zurück zum Zitat Thomas E.J., Studdert D.M., Burstin H.R., et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care 2000; 38: 261–271PubMedCrossRef Thomas E.J., Studdert D.M., Burstin H.R., et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care 2000; 38: 261–271PubMedCrossRef
4.
Zurück zum Zitat Classen D.C., Pestotnik S.L., Evans R.S., et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301–306PubMedCrossRef Classen D.C., Pestotnik S.L., Evans R.S., et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301–306PubMedCrossRef
5.
Zurück zum Zitat Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200–1205PubMedCrossRef Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200–1205PubMedCrossRef
6.
Zurück zum Zitat Miller R.R. Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1974; 134: 219–223PubMedCrossRef Miller R.R. Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1974; 134: 219–223PubMedCrossRef
7.
Zurück zum Zitat Pouyanne P., Haramburu F., Imbs J.L., et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef Pouyanne P., Haramburu F., Imbs J.L., et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef
8.
Zurück zum Zitat Fattinger K., Roos M., Vergeres P., et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–167PubMedCrossRef Fattinger K., Roos M., Vergeres P., et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–167PubMedCrossRef
9.
Zurück zum Zitat Martin R.M., Biswas P.N., Freemantle S.N., et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505–511PubMedCrossRef Martin R.M., Biswas P.N., Freemantle S.N., et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505–511PubMedCrossRef
10.
Zurück zum Zitat van der Klauw M.M., Wilson J.H., Stricker B.H. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974–1994). Am J Hematol 1998; 57: 206–211PubMedCrossRef van der Klauw M.M., Wilson J.H., Stricker B.H. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974–1994). Am J Hematol 1998; 57: 206–211PubMedCrossRef
11.
Zurück zum Zitat van der Klauw M.M., Wilson J.H., Stricker B.H. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974–1994) and review of the literature. Clin Exp Allergy 1996; 26: 1355–1363PubMedCrossRef van der Klauw M.M., Wilson J.H., Stricker B.H. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974–1994) and review of the literature. Clin Exp Allergy 1996; 26: 1355–1363PubMedCrossRef
12.
Zurück zum Zitat Figueras A., Capella D., Castel J.M., et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and entericcoated formulations. Eur J Clin Pharmacol 1994; 47: 297–303PubMedCrossRef Figueras A., Capella D., Castel J.M., et al. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and entericcoated formulations. Eur J Clin Pharmacol 1994; 47: 297–303PubMedCrossRef
13.
Zurück zum Zitat Makkar R.R., Fromm B.S., Steinman R.T., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–2597PubMedCrossRef Makkar R.R., Fromm B.S., Steinman R.T., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–2597PubMedCrossRef
14.
Zurück zum Zitat Tran C., Knowles S.R., Liu B.A., et al. Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38: 1003–1009PubMedCrossRef Tran C., Knowles S.R., Liu B.A., et al. Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38: 1003–1009PubMedCrossRef
15.
Zurück zum Zitat Domecq C., Naranjo C.A., Ruiz I., et al. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18: 362–366PubMed Domecq C., Naranjo C.A., Ruiz I., et al. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18: 362–366PubMed
16.
Zurück zum Zitat Naldi L., Conforti A., Venegoni M., et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839–846PubMedCrossRef Naldi L., Conforti A., Venegoni M., et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839–846PubMedCrossRef
17.
Zurück zum Zitat Kando J.C., Yonkers K.A., Cole J.O. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1–6PubMedCrossRef Kando J.C., Yonkers K.A., Cole J.O. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1–6PubMedCrossRef
18.
Zurück zum Zitat Harris R.Z., Benet L.Z., Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–239PubMedCrossRef Harris R.Z., Benet L.Z., Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–239PubMedCrossRef
19.
Zurück zum Zitat Ochs H.R., Greenblatt D.J., Divoll M., et al. Diazepam kinetics in relation to age and sex. Pharmacology 1981; 23: 24–30PubMedCrossRef Ochs H.R., Greenblatt D.J., Divoll M., et al. Diazepam kinetics in relation to age and sex. Pharmacology 1981; 23: 24–30PubMedCrossRef
20.
Zurück zum Zitat Wrighton S.A., Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21PubMedCrossRef Wrighton S.A., Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21PubMedCrossRef
21.
Zurück zum Zitat Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275–283PubMedCrossRef Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275–283PubMedCrossRef
22.
Zurück zum Zitat Schmucker D.L., Woodhouse K.W., Wang R.K., et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365–374PubMedCrossRef Schmucker D.L., Woodhouse K.W., Wang R.K., et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365–374PubMedCrossRef
23.
Zurück zum Zitat Divoll M., Greenblatt D.J., Harmatz J.S., et al. Effect of age and gender on disposition of temazepam. J Pharm Sci 1981; 70: 1104–1107PubMedCrossRef Divoll M., Greenblatt D.J., Harmatz J.S., et al. Effect of age and gender on disposition of temazepam. J Pharm Sci 1981; 70: 1104–1107PubMedCrossRef
24.
Zurück zum Zitat Benton R.E., Sale M., Flockhart D.A., et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413–418PubMedCrossRef Benton R.E., Sale M., Flockhart D.A., et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413–418PubMedCrossRef
25.
Zurück zum Zitat Yonkers K.A., Kando J.C., Cole J.O., et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587–595PubMed Yonkers K.A., Kando J.C., Cole J.O., et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587–595PubMed
26.
Zurück zum Zitat Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23: 483–507PubMedCrossRef Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23: 483–507PubMedCrossRef
27.
Zurück zum Zitat Park B.K., Kitteringham N.R., Powell H., Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39–60PubMedCrossRef Park B.K., Kitteringham N.R., Powell H., Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39–60PubMedCrossRef
28.
Zurück zum Zitat Yawalkar N., Hari Y., Frutig K., et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647–652PubMedCrossRef Yawalkar N., Hari Y., Frutig K., et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647–652PubMedCrossRef
29.
Zurück zum Zitat Yawalkar N., Egli F., Hari Y., et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Exp Allergy 2000; 30: 847–855CrossRef Yawalkar N., Egli F., Hari Y., et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Exp Allergy 2000; 30: 847–855CrossRef
30.
Zurück zum Zitat Borda I., Jick H., Slone D., et al. Studies of drug usage in five Boston hospitals. JAMA 1967; 202: 506–510PubMedCrossRef Borda I., Jick H., Slone D., et al. Studies of drug usage in five Boston hospitals. JAMA 1967; 202: 506–510PubMedCrossRef
31.
Zurück zum Zitat Svarstad B.L., Cleary P.D., Mechanic D., et al. Gender differences in the acquisition of prescribed drugs: an epidemiological study. Med Care 1987; 25: 1089–1098PubMedCrossRef Svarstad B.L., Cleary P.D., Mechanic D., et al. Gender differences in the acquisition of prescribed drugs: an epidemiological study. Med Care 1987; 25: 1089–1098PubMedCrossRef
32.
Zurück zum Zitat Sihvo S., Klaukka T., Martikainen J., et al. Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population. Eur J Clin Pharmacol 2000; 56: 495–499PubMedCrossRef Sihvo S., Klaukka T., Martikainen J., et al. Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population. Eur J Clin Pharmacol 2000; 56: 495–499PubMedCrossRef
33.
Zurück zum Zitat Al-Windi A., Elmfeldt D., Svardsudd K. The relationship between age, gender, wellbeing and symptoms, and the use of pharmaceuticals, herbal medicines and selfcare products in a Swedish municipality. Eur J Clin Pharmacol 2000; 56: 311–317PubMedCrossRef Al-Windi A., Elmfeldt D., Svardsudd K. The relationship between age, gender, wellbeing and symptoms, and the use of pharmaceuticals, herbal medicines and selfcare products in a Swedish municipality. Eur J Clin Pharmacol 2000; 56: 311–317PubMedCrossRef
Metadaten
Titel
Do Women Have More Adverse Drug Reactions?
verfasst von
Dr Marius Rademaker
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2001
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200102060-00001

Weitere Artikel der Ausgabe 6/2001

American Journal of Clinical Dermatology 6/2001 Zur Ausgabe

Adis Drug Evaluation

Tacrolimus Ointment

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.